Biren Amin
Stock Analyst at Piper Sandler
(3.65)
# 904
Out of 5,182 analysts
73
Total ratings
43.08%
Success rate
10.53%
Average return
Main Sectors:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $875 | $744.44 | +17.54% | 3 | Mar 31, 2026 | |
| CNTX Context Therapeutics | Maintains: Overweight | $4 → $7 | $2.34 | +199.15% | 2 | Mar 24, 2026 | |
| IMTX Immatics | Assumes: Buy | $18 | $11.35 | +58.59% | 2 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $7 → $8 | $2.25 | +255.56% | 4 | Mar 13, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $125 → $140 | $86.68 | +61.51% | 1 | Feb 26, 2026 | |
| OKYO OKYO Pharma | Initiates: Overweight | $7 | $1.58 | +343.04% | 1 | Feb 20, 2026 | |
| CATX Perspective Therapeutics | Initiates: Overweight | $16 | $4.27 | +274.71% | 1 | Feb 19, 2026 | |
| IRD Opus Genetics | Initiates: Overweight | $7 | $5.12 | +36.72% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $23.37 | +105.39% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $20.98 | -23.74% | 12 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $98 | $74.52 | +31.51% | 4 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $67 | $9.76 | +586.48% | 2 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $31 | $9.52 | +225.63% | 2 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $95 | $54.02 | +75.86% | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $6 | $4.41 | +36.05% | 1 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $17 | $7.50 | +126.67% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $39.51 | -3.82% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $1.79 | +570.39% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $32.99 | +115.25% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $10.08 | +247.22% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $23.49 | -10.60% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $115.07 | -0.06% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $40.95 | -21.86% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $4.09 | -26.65% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $4.25 | +1,547.06% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,550 | $4.51 | +56,441.02% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.58 | +1,418.99% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $6.46 | +426.32% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.12 | +418,660.47% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $4.29 | +133.10% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $66.59 | +51.67% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $128.04 | -46.11% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $426.01 | -63.62% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $6.43 | +2,015.09% | 4 | Mar 6, 2017 |
Regeneron Pharmaceuticals
Mar 31, 2026
Assumes: Overweight
Price Target: $875
Current: $744.44
Upside: +17.54%
Context Therapeutics
Mar 24, 2026
Maintains: Overweight
Price Target: $4 → $7
Current: $2.34
Upside: +199.15%
Immatics
Mar 16, 2026
Assumes: Buy
Price Target: $18
Current: $11.35
Upside: +58.59%
Allogene Therapeutics
Mar 13, 2026
Maintains: Overweight
Price Target: $7 → $8
Current: $2.25
Upside: +255.56%
Kymera Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $125 → $140
Current: $86.68
Upside: +61.51%
OKYO Pharma
Feb 20, 2026
Initiates: Overweight
Price Target: $7
Current: $1.58
Upside: +343.04%
Perspective Therapeutics
Feb 19, 2026
Initiates: Overweight
Price Target: $16
Current: $4.27
Upside: +274.71%
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $5.12
Upside: +36.72%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $23.37
Upside: +105.39%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $20.98
Upside: -23.74%
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $74.52
Upside: +31.51%
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $9.76
Upside: +586.48%
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $9.52
Upside: +225.63%
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $54.02
Upside: +75.86%
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $4.41
Upside: +36.05%
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $7.50
Upside: +126.67%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $39.51
Upside: -3.82%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $1.79
Upside: +570.39%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $32.99
Upside: +115.25%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $10.08
Upside: +247.22%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $23.49
Upside: -10.60%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $115.07
Upside: -0.06%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $40.95
Upside: -21.86%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $4.09
Upside: -26.65%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $4.25
Upside: +1,547.06%
Jan 11, 2021
Initiates: Buy
Price Target: $2,550
Current: $4.51
Upside: +56,441.02%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $1.58
Upside: +1,418.99%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $6.46
Upside: +426.32%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.12
Upside: +418,660.47%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $4.29
Upside: +133.10%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $66.59
Upside: +51.67%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $128.04
Upside: -46.11%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $426.01
Upside: -63.62%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $6.43
Upside: +2,015.09%